Stem cell therapy takes a giant leap

August 2008
New Scientist;8/23/2008, Vol. 199 Issue 2670, p5
The author reflects on the use of embryonic stem cells (ESCs) to repair damaged spinal cords, hearts, livers, bones and pancreas.


Related Articles

  • ACT Carries the Torch for hESC Therapies Post-Geron Exit. Moran, Nuala // BioWorld Today;11/23/2011, Vol. 22 Issue 228, p2 

    The article reports on the announcement by Advanced Cell Technology (ACT) Inc. that it is about to publish results from its Phase I/II trials of retinal pigmented epithelial (RPE) cells and human embryonic stem cell (hESC)-based therapies following the abrupt withdrawal of Geron Inc. from the...

  • Stem Cell Study Patients May Need Long-Term Monitoring. Young, Donna // BioWorld Today;4/11/2008, Vol. 19 Issue 71, p1 

    The article focuses on the need for patients involved in studies of cellular therapies derived from human embryonic stem cells (hESCs) to be monitored throughout their lifetime for tumors or other abnormalities, according to the U.S. Food and Drug Administration's Cellular, Tissue and Gene...

  • Eyes open to stem cells: safety trial may pave the way for cell therapy to treat retinal disease in patients. Medina, Reinhold J.; Archer, Desmond B.; Stitt, Alan W. // Stem Cell Research & Therapy;2011, Vol. 2 Issue 6, p1 

    A clinical trial using human embryonic stem cell (hESC) therapy for an inherited retinal degenerative disease is about to commence. The Advanced Cell Technology (ACT) trial will treat patients with Stargardt's macular dystrophy using transplanted retinal pigment epithelium derived from hESCs....

  • Allogeneic stromal cell implantation in brain tissue leads to robust microglial activation. Tambuyzer, Bart R.; Bergwerf, Irene; De Vocht, Nathalie; Reekmans, Kristien; Daans, Jasmijn; Jorens, Philippe G.; Goossens, Herman; Ysebaert, Dirk K.; Chatterjee, Shyama; Van Marck, Eric; Berneman, Zwi N.; Ponsaerts, Peter // Immunology & Cell Biology;May2009, Vol. 87 Issue 4, p267 

    Although adult and embryonic stem cell-based therapy for central nervous system (CNS) injury is being developed worldwide, less attention is given to the immunological aspects of allogeneic cell implantation in the CNS. The latter is of major importance because, from a practical point of view,...

  • Research Moves Forward. Troop, Alan // New Mobility;Mar2013, Vol. 24 Issue 234, p24 

    The article discusses the Miami Project to Cure Paralysis in Miami, Florida, which is the only approved stem cell therapy trial for spinal cord injury (SCI) in the U.S. It notes that Marc Buoniconti initiated the clinical trial of the Miami Project, which will ensure the effectiveness and safety...

  • Direct Reprogramming. Marb├ín, Eduardo; Cingolani, Eugenio // JAMA: Journal of the American Medical Association;7/7/2015, Vol. 314 Issue 1, p19 

    The authors comment on the direct reprogramming of stem cells for therapeutics. Topics covered include concerns that have restricted in vivo applications of tissues and organs to be recreated from embryonic stem cells, the limitations of induced stem cells as well as the complexity of...

  • Progress toward the clinical application of patient-specific pluripotent stem cells. Kiskinis, Evangelos; Eggan, Kevin // Journal of Clinical Investigation;Jan2010, Vol. 120 Issue 1, p51 

    Induced pluripotent stem (iPS) cells are generated by epigenetic reprogramming of somatic cells through the exogenous expression of transcription factors. These cells, just like embryonic stem cells, are likely to have a major impact on regenerative medicine, because they self-renew and retain...

  • Cells Show Promise for Parkinson's.  // Technology Review;Jul2008, Vol. 111 Issue 4, p92 

    The article presents a study that assesses the capabilities of brain cells developed from skin cells to alleviate the symptoms and pain in Parkinson's disease. Rudolf Jaenish and colleagues administered the study by transforming mouse skin cells into undifferential cells induced into four...

  • Late Abstracts: Presented at the American Society of Gene & Cell Therapy's 14th Annual Meeting, May 18-21, 2011, Seattle, Washington.  // Molecular Therapy;Jul2011, Vol. 19 Issue 7, p1360 

    The article presents abstracts related to gene and cell therapy which include research on the use of microRNA (miRNA) in inhibiting liver tumor in a mouse model, the potential of human embryonic stem cells (hESC) in treating diabetes, and the development of a retroviral replicating vector (RRV)...


Other Topics